Molecular Partners announces upcoming poster presentations at the SITC 2024 Annual Meeting

Preclinical proof-of-concept data supports the CD3 Switch-DARPin platform for those engaging T cells with enhanced function in solid tumors

Biomarker data from the completed Phase 1 study MP0317 (FAP x CD40) demonstrates intentional and marked modulation of the tumor microenvironment

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 4, 2024 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotechnology company developing a new class of custom drug proteins known as DARPin drugs , announced today that the Company will introduce proof-of-concept data for a novel CD3 Switch-DARPin designed to overcome ongoing challenges in T cell engagement in solid tumors, and will present additional analyzes from its Phase 1 study of MP0317 in patients with advanced solid tumors at the annual meeting Society for Immunotherapy of Cancer (SITC) in 2024, taking place November 8-10 in Houston, Texas.

Details of the poster presentation are as follows:

Title: Unlocking precision: next-generation multispecific CD3-DARPin switch with improved function to address current limitations in T cell engagement in ovarian cancer

Abstract and poster number: 842

Title: Comprehensive biomarker analyzes from a phase 1 study reveal marked modulation of the tumor microenvironment in patients with advanced solid tumors treated with MP0317, DARPin, a FAP-localized CD40 agonist

Abstract and poster number: 612

Time and location: November 9, 2024 from 9:00 a.m. to 8:30 p.m. (Polish time); AB exhibition halls

Posters will be made available on the Molecular Partners website after the conference.

About DARPin therapy

Therapeutic drugs DARPin (Designed Ankyrin Repeat Protein) are a new class of specially developed protein drugs based on naturally binding proteins that open new dimensions of multifunctionality and multidirectional specificity in drug design. DARPin’s flexible architecture, intrinsic potential for high affinity and specificity, small size, and high stability offer advantages in drug design compared to other currently available protein-based therapeutics. DARPin candidates can be radically simple, with a single DARPin unit acting as a delivery vector for a specific target; or multispecific, with the potential to engage more than five targets and combine multiple and contingent functionalities in a unique DARPin drug candidate. The DARPin platform is designed to be a fast and cost-effective drug discovery engine, enabling the production of drug candidates with optimized properties and high production throughput. DARPin drugs have been clinically validated in several therapeutic areas and developed to the registration stage.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotechnology company pioneering the design and development of DARPin therapeutics to address medical challenges that other treatments cannot easily address. The company has programs at various stages of preclinical and clinical development, the main focus of which is oncology. Molecular Partners leverages the benefits of DARPins to deliver unique solutions to patients through its own programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in Zurich, Switzerland and Concord, Massachusetts, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter/X @MolecularPrtnrs

For further details please contact:

Seth Lewis, vice president of investor relations and strategy

Concord, Massachusetts, USA

(email protected)

Tel: +1 781 420 2361

Dr. Laura Jeanbart, Director of Portfolio Management and Communications

Zurich-Schlieren, Switzerland

(email protected)

Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that are not statements of historical fact may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding the timing of reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and the RDT and Switch-DARPin platforms; selection and development of future programs; Molecular Partners’ cooperation with Orano Med, covering the benefits and results that can be achieved through cooperation; and Molecular Partners’ expected business and financial prospects, including anticipated 2024 cash expenditures and uses and current cash flow expectations. These statements may be identified by words such as “target”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions and are based on Molecular Partners current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include plans for the development and potential commercialization of product candidates; Molecular Partners’ dependence on external partners and collaborators over which it may not always have full control; Molecular Partners’ ongoing and planned clinical and preclinical studies of its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing and ability of Molecular Partners to obtain and maintain regulatory approvals for its product candidates; the scope of clinical trials potentially required for Molecular Partners’ product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners’ product candidates; the potential that Molecular Partners’ product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners’ preclinical research, clinical trials or operations or the businesses of third parties on which it relies; Molecular Partners’ plans and development of any new indications for its product candidates; Molecular Partners’ commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners’ position on intellectual property; Molecular Partners’ ability to identify and license additional products; unanticipated factors, in addition to the foregoing, that may affect Molecular Partners’ financial and business forecasts and guidance; and other risks and uncertainties described in the Risk Factors section of Molecular Partners’ Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and other documents filed by Molecular Partners with the SEC. These documents are available on the investor page of the Molecular Partners website at www.molecularpartners.com. In addition, this press release contains information regarding interim data as of a given cut-off date for data whose results may differ from those that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this press release, and Molecular Partners assumes no obligation and does not intend to update any forward-looking information. looking at statements, whether as a result of new information, future events or other reasons.